---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009081"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:34:18.878161+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CervoMed Phase 2b DLB data show greater benefit in patients without AD co-pathology

## Summary
- At pTau181 <21 pg/mL, neflamapimod showed CDR-SB improvement of -1.11 vs placebo (p=0.005) in within-participant analysis.
- PK/PD analyses identified therapeutic trough concentration threshold of 4 ng/mL; DP Batch B achieved this in 75% of patients vs 50% for Batch A.
- Planned Phase 3 trial will use pTau181 <21 pg/mL enrichment, expecting 80-90% of patients without AD co-pathology.
- Data presented March 21, 2026 at AD/PD 2026 Conference in Copenhagen, Denmark.

## SEC filing metadata
- accession: 0001437749-26-009081
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926009081/0001437749-26-009081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926009081/crvo20260319_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009081
- JSON: https://secwatch.observer/filing/0001437749-26-009081.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.